BI-1910

N/A

Report date: 2023/12/06 17:12:57

Base Information

Drug NameBI-1910

Drug Alias NameBI-1910

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody

Mechanisms of ActionT lymphocytes stimulantsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsTumor necrosis factor receptor superfamily member 1B agonists

TargetsTumor necrosis factor receptor superfamily member 1B

Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungCarcinoma, Hepatocellular

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySwedenDenmarkGermany +[4]

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesBioinvent International Ab

China Registration ClassN/A

Develop Information

Active CompaniesBioinvent International Ab

Inactive CompaniesN/A

Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungCarcinoma, Hepatocellular

Inactive IndicationsN/A

Other Information

ATC CodeN/A